Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1486-1494

  Loureiro, Ana I ^a   Fernandes Lopes, Carlos ^a   Bonifácio, Maria J ^a   Wright, Lyndon C ^a   Soares da Silva, Patricio ^a,b  

^a Bial ^*  (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; DICLOFENAC; DRUG METABOLITE; ESLICARBAZEPINE; ESLICARBAZEPINE GLUCURONIDE; IMIPRAMINE; PROPOFOL; RECOMBINANT ENZYME; RECOMBINANT GLUCURONOSYLTRANSFERASE; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A1; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A10; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A3; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A4; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A6; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A7; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A8; RECOMBINANT GLUCURONOSYLTRANSFERASE 1A9; RECOMBINANT GLUCURONOSYLTRANSFERASE 2B15; RECOMBINANT GLUCURONOSYLTRANSFERASE 2B17; RECOMBINANT GLUCURONOSYLTRANSFERASE 2B4; RECOMBINANT GLUCURONOSYLTRANSFERASE 2B7; TESTOSTERONE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITOR COMPLEX; ENZYME KINETICS; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTICONVULSANTS; DIBENZAZEPINES; ESCHERICHIA COLI; GLUCURONIDASE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; LIVER; MICE; MICROSOMES, LIVER; SERUM ALBUMIN, BOVINE; TRIFLUOPERAZINE; URIDINE DIPHOSPHATE GLUCURONIC ACID;

BOVINAE; ESCHERICHIA COLI;

EID: 80051986999     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.038620     Document Type: Article

References (39)

1. Almeida L., Bialer M, and Soares-da-Silva P. (2009) Eslicarbazepine acetate, in The Treatment of Epilepsy (Shorvon S, Peruca E, and Engel J eds) pp 485-498, Blackwell Publishing, Oxford.
2. Almeida L., Nunes T., Sicard E., Rocha JF, Falcão A, Brunet JS, Lefebvre M, and Soares-da-Silva P (2010) Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand 121:257-264.
3. Almeida L., Potgieter J.H., Maia J., Potgieter M.A., Mota F, and Soares-da-Silva P. (2008) Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 64:267-273.
4. Almeida L and Soares-da-Silva P. (2007) Eslicarbazepine acetate (BIA 2- 093). Neurotherapeutics 4:88-96.
5. Ben-Menachem E., Gabbai A.A., Hufnagel A., Maia J., Almeida L, and Soares-da-Silva P. (2010) Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Research 89:278-285.
6. Bernus I., Dickinson R.G., Hooper WD, and Eadie M.J. (1997) The mechanism of the carbamazepine- Valproate interaction in humans. Br J Clin Pharmacol 44:21-27. (Pubitemid 27296791)
7. Borlak J., Gasparic A., Locher M., Schupke H, and Hermann R. (2006) N- Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism 55:711-721.
8. Bowalgaha K., Elliot D.J., Mackenzie P.I., Knights KM, and Miners J.O. (2007) The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos 35:363-370.
9. Brown ME and El-Mallakh R.S. (2010) Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial- Onset seizures. Ther Clin Risk Manag 6:103-109.
10. CHMP (2009) CHMP assessment report for Zebinix (eslicarbazepine acetate), in Procedure No. EMEA/H/C/000988 (EMEA/304525/2009 DR ed, pp 80, European Medicines Agency, London.
11. Ebner T and Burchell B. (1993) Substrate specificities of two stably expressed human liver UDP- Glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 21:50-55. (Pubitemid 23052221)
12. Elger C., Halász P., Maia J., Almeida L., Soares-da-Silva P, and BIA-2093-301 Investigators Study Group (2009) Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial- Onset seizures: a randomized, double- Onset seizures: a randomized, doubleBlind, placebo- Onset seizures: a randomized, doubleBlind, placeboControlled, parallel- Onset seizures: a randomized, doubleBlind, placeboControlled, parallelGroup phase III study. Epilepsia 50:454-463.
13. Ethell B.T., Anderson GD, and Burchell B. (2003) The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP- Glucuronosyltransferases. Biochem Pharmacol 65:1441-1449. (Pubitemid 36555832)
14. Flesch G. (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24:185-203.
15. Gil-Nagel A., Lopes-Lima J., Almeida L., Maia J., Soares-da-Silva P, and BIA-2093-303 Investigators Study Group (2009) Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial- Onset seizures. Acta Neurol Scand 120:281-287.
16. Green M.D., King C.D., Mojarrabi B., Mackenzie PI, and Tephly T.R. (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP- Glucuronosyltransferase 1A3. Drug Metab Dispos 26:507-512. (Pubitemid 28498354)
17. Hainzl D., Parada A, and Soares-da-Silva P. (2001) Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- And R(-)- And R()10,11- And R()10,11Dihydro-10- And R()10,11Dihydro10Hydroxy carbamazepine. Epilepsy Res 44:197-206. (Pubitemid 32452229)
18. Hanioka N., Ozawa S., Jinno H., Ando M., Saito Y, and Sawada J. (2001) Human liver UDPglucuronosyltransferase isoforms involved in the glucuronidation of 7- Ethyl-10- Ethyl10Hydroxycamptothecin. Xenobiotica 31:687-699. (Pubitemid 33001093)
19. Hermann R., Knebel N.G., Niebch G., Richards L., Borlak J, and Locher M. (2003) Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 58:795-802. (Pubitemid 36577809)
20. King C., Tang W., Ngui J., Tephly T, and Braun M. (2001) Characterization of rat and human UDP- Glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 61:49-53. (Pubitemid 32409686)
21. Kostrubsky S.E., Sinclair J.F., Strom S.C., Wood S., Urda E., Stolz D.B., Wen Y.H., Kulkarni S, and Mutlib A. (2005) Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP- Glucuronosyltransferases in cultured human hepatocytes. Toxicol Sci 87: 146-155. (Pubitemid 41222666)
22. Mackenzie P.I., Bock K.W., Burchell B., Guillemette C., Ikushiro S., Iyanagi T., Miners J.O., Owens IS, and Nebert D.W. (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685. (Pubitemid 41345319)
23. Maggs J.L., Pirmohamed M., Kitteringham NR, and Park B.K. (1997) Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. Drug Metab Dispos 25:275-280. (Pubitemid 27120571)
24. Maia J., Almeida L, Falca&tild;o A, Soares E, Mota F, Potgieter MA, Potgieter JH, and Soares-da-Silva P (2008) Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 46:119-130. (Pubitemid 351721154)
25. Nakajima M., Tanaka E., Kobayashi T., Ohashi N., Kume T, and Yokoi T. (2002) Imipramine N- Glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP- Glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDPGlucuronosyltransferase isoforms. Drug Metab Dispos 30:636-642. (Pubitemid 34579095)
26. Nakajima M., Yamanaka H., Fujiwara R., Katoh M, and Yokoi T. (2007) Stereoselective glucuronidation of 5- (4′- (4′Hydroxyphenyl)-5- (4′Hydroxyphenyl)5Phenylhydantoin by human UDP- (4′Hydroxyphenyl) 5Phenylhydantoin by human UDPGlucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT- (4′Hydroxyphenyl)5Phenylhydantoin by human UDPGlucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGTUGT interactions. Drug Metab Dispos 35:1679-1686.
27. Nunes T., Sicard E., Almeida L, Falcão A, Rocha JF, Brunet JS, Lefebvre M, and Soares-da-Silva P (2010) Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr Med Res Opin 26:1355-1362.
28. Riva R., Albani F., Contin M, and Baruzzi A. (1996) Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet 31:470-493. (Pubitemid 26413673)
29. Rowland A., Elliot D.J., Williams J.A., Mackenzie P.I., Dickinson RG, and Miners J.O. (2006) In vitro characterization of lamotrigine N2- Glucuronidation and the lamotrigine- Glucuronidation and the lamotrigineValproic acid interaction. Drug Metab Dispos 34:1055-1062. (Pubitemid 43763765)
30. Rowland A., Gaganis P., Elliot D.J., Mackenzie P.I., Knights KM, and Miners J.O. (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP- Glucuronosyltransferase 2B7 activity by albumin: implications for in vitro- Glucuronosyltransferase 2B7 activity by albumin: implications for in vitroIn vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
31. Staines A.G., Coughtrie MW, and Burchell B. (2004) N- Glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther 311:1131-1137. (Pubitemid 39612720)
32. Strassburg C.P., Kneip S., Topp J., Obermayer-Straub P., Barut A., Tukey RH, and Manns M.P. (2000) Polymorphic gene regulation and interindividual variation of UDP- Glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
33. Turgeon D., Carrier J.S., Chouinard S, and Bélanger A. (2003) Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab Dispos 31:670-676. (Pubitemid 36444177)
34. Uchaipichat V., Mackenzie P.I., Elliot DJ, and Miners J.O. (2006a) Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP Glucuronosyltransferases. Drug Metab Dispos 34:449-456.
35. Uchaipichat V., Winner L.K., Mackenzie P.I., Elliot D.J., Williams JA, and Miners J.O. (2006b) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: The effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
36. Wen Z., Martin D.E., Bullock P., Lee KH, and Smith P.C. (2007) Glucuronidation of anti- HIV drug candidate bevirimat: identification of human UDP- HIV drug candidate bevirimat: identification of human UDPGlucuronosyltransferases and species differences. Drug Metab Dispos 35:440-448. (Pubitemid 46333907)
37. Xu L., Krenitsky D.M., Seacat A.M., Butenhoff J.L., Tephly TR, and Anders M.W. (2006) Nglucuronidation of perfluorooctanesulfonamide by human, rat, dog, and monkey liver microsomes and by expressed rat and human UDP- glucuronosyltransferases. Drug Metab Dispos 34:1406-1410. (Pubitemid 44079883)
38. Zenser T.V., Lakshmi VM, and Davis B.B. (1999) Human and Escherichia coli beta- Glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4- Glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4Aminobiphenyl, and their hydroxy metabolites. Drug Metab Dispos 27:1064-1067. (Pubitemid 29409643)
39. Zhu B., Bush D., Doss G.A., Vincent S., Franklin RB, and Xu S. (2008) Characterization of 1′- Hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos 36: 331-338. (Pubitemid 351185745)